- Home
- CRT vs IMRX Comparison
CRT vs IMRX Comparison
Compare CRT & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- IMRX
- Stock Information
- Founded
- CRT 1991
- IMRX 2008
- Country
- CRT United States
- IMRX United States
- Employees
- CRT N/A
- IMRX N/A
- Industry
- CRT Oil & Gas Production
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- IMRX Health Care
- Exchange
- CRT Nasdaq
- IMRX Nasdaq
- Market Cap
- CRT 64.0M
- IMRX 62.7M
- IPO Year
- CRT 1992
- IMRX 2021
- Fundamental
- Price
- CRT $10.32
- IMRX $1.27
- Analyst Decision
- CRT
- IMRX Strong Buy
- Analyst Count
- CRT 0
- IMRX 2
- Target Price
- CRT N/A
- IMRX $12.50
- AVG Volume (30 Days)
- CRT 39.7K
- IMRX 170.4K
- Earning Date
- CRT 01-01-0001
- IMRX 05-06-2025
- Dividend Yield
- CRT 8.33%
- IMRX N/A
- EPS Growth
- CRT N/A
- IMRX N/A
- EPS
- CRT 0.95
- IMRX N/A
- Revenue
- CRT $6,623,430.00
- IMRX N/A
- Revenue This Year
- CRT N/A
- IMRX N/A
- Revenue Next Year
- CRT N/A
- IMRX N/A
- P/E Ratio
- CRT $10.91
- IMRX N/A
- Revenue Growth
- CRT N/A
- IMRX N/A
- 52 Week Low
- CRT $8.88
- IMRX $1.00
- 52 Week High
- CRT $14.98
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- CRT 43.03
- IMRX 34.48
- Support Level
- CRT $9.20
- IMRX $1.23
- Resistance Level
- CRT $11.46
- IMRX $1.38
- Average True Range (ATR)
- CRT 0.90
- IMRX 0.11
- MACD
- CRT -0.09
- IMRX -0.01
- Stochastic Oscillator
- CRT 27.25
- IMRX 26.42
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States based trust. Its principal asset is the net profits interests. The net profits interests are derived from producing royalty, overriding royalty interests, and working interests properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.